Skip to main content

Table 3 Number and site of metastases in the patients treated with a pemetrexed-containing therapy

From: Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

  Total (n = 314) Good responder (n = 92) Poor responder (n = 222) P-value
Number of metastatic sites ≥2 201 (64.0) 44 (47.8) 157 (70.7) <0.001
Site of metastases
Lung 152 (48.4) 48 (52.2) 104 (46.8) 0.390
Pleura 144 (45.9) 39 (42.4) 105 (47.3) 0.427
Bone 125 (39.8) 29 (31.5) 96 (43.2) 0.053
Brain 77 (24.5) 18 (19.6) 59 (26.6) 0.189
Adrenal gland 45 (14.3) 3 (3.3) 42 (18.9) <0.001
Liver 43 (13.7) 5 (5.4) 38 (17.1) 0.006
Pericardial effusion 20 (6.4) 5 (5.4) 15 (6.8) 0.662
Previous surgical therapy 68 (21.7) 37 (40.2) 31 (14.0) <0.001
  1. Data are shown as n (%) per each group, unless otherwise noted